Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho

Nkarta (NASDAQ:NKTX) had its price objective cut by Mizuho from $14.00 to $12.00 in a report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

Several other analysts have also recently weighed in on NKTX. Needham & Company LLC lifted their price objective on shares of Nkarta from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a report on Friday. Finally, Wall Street Zen downgraded shares of Nkarta from a “hold” rating to a “sell” rating in a research report on Saturday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $11.33.

Nkarta Price Performance

NKTX stock opened at $2.11 on Tuesday. Nkarta has a fifty-two week low of $1.42 and a fifty-two week high of $2.81. The stock has a market capitalization of $156.75 million, a price-to-earnings ratio of -1.51 and a beta of 0.47. The business’s fifty day moving average price is $2.28 and its two-hundred day moving average price is $2.10.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Wednesday, March 25th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Research analysts expect that Nkarta will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 26,046 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $2.07, for a total value of $53,915.22. Following the completion of the transaction, the chief executive officer owned 390,023 shares of the company’s stock, valued at $807,347.61. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nkarta

Hedge funds have recently bought and sold shares of the company. Hsbc Holdings PLC raised its position in shares of Nkarta by 70.0% in the 4th quarter. Hsbc Holdings PLC now owns 161,434 shares of the company’s stock valued at $299,000 after buying an additional 66,479 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Nkarta by 28.8% during the 4th quarter. Invesco Ltd. now owns 150,476 shares of the company’s stock worth $278,000 after acquiring an additional 33,632 shares during the period. XTX Topco Ltd boosted its position in shares of Nkarta by 698.4% during the 4th quarter. XTX Topco Ltd now owns 134,730 shares of the company’s stock worth $249,000 after acquiring an additional 117,856 shares in the last quarter. Man Group plc boosted its position in shares of Nkarta by 102.7% during the 4th quarter. Man Group plc now owns 88,438 shares of the company’s stock worth $164,000 after acquiring an additional 44,810 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its stake in Nkarta by 22.8% in the fourth quarter. Bridgeway Capital Management LLC now owns 107,800 shares of the company’s stock valued at $199,000 after acquiring an additional 20,000 shares during the last quarter. 80.54% of the stock is owned by institutional investors.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.